FDA approves Pfizer's Lyrica for the treatment of the two most common forms of neuropathic pain
NEW YORK, December 31, 2004 - Pfizer Inc said today that it has received approval from the U.S. Food and Drug Administration (FDA) to market Lyrica (pregabalin capsules) for the management of neuropathic pain associated with diabetic peripheral neuropathy (DPN) and postherpetic neuralgia (PHN). Lyrica is the first FDA-approved treatment for both of these neuropathic pain states, which are distin...Pfizer's antifungal medicine VFEND receives FDA approval
NEW YORK, December 28, 2004 Pfizer Inc announced today that the U.S. Food and Drug Administration (FDA) approved the use of its extended-spectrum antifungal VFEND (voriconazole; IV for injection, tablets, and oral suspension) for the treatment of candidemia in nonneutropenic patients (those without low white blood cell counts) and the following Candida infections: disseminated (deep tissue) infe...New data sets survival benchmark for Pfizer's ELLENCE
San Antonio, Dec. 10, 2004 Today, results of a study presented at the 27th Annual San Antonio Breast Cancer Symposium show that an ELLENCE (epirubicin hydrochloride injection) based chemotherapy regimen delivers survival benefits when used alone or in combination with docetaxel. The results of the study, which compares a sequential regimen of FEC 100 (fluorouracil 500 mg/m2, epirubicin 100 mg/m...Pfizer's VFEND (R) as effective in treating Candidemia as two-drug standard of care, study shows
Prague, Czech Republic, May 3, 2004 Pfizer Inc's antifungal VFEND (voriconazole) was shown to be as effective as a regimen of amphotericin B followed by fluconazole in the primary treatment of candidemia, including hard-to-treat non-albicans species, according to data presented today at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). Candidemia is the most deadl...Pfizer's VFEND(R) receives FDA approval for treatment of esophageal candidiasis
NEW YORK, November 17, 2003 - Pfizer Inc said today that it has received U.S. Food and Drug Administration (FDA) approval to market VFEND (voriconazole), a broad spectrum antifungal medicine, for the treatment of esophageal candidiasis. ...... Candida organisms are normally found on skin and mucous membranes in healthy individuals, but in persons whose immune systems are weakened or compromised...Pfizer's ZYVOX(TM) more effective than vancomycin in treating complicated SSTIs caused by MRSA
San Diego, October 10, 2003 Clinical cure rates were significantly better in patients treated with Pfizer's antibiotic ZYVOX was as effective as all comparators. In addition, ZYVOX shortened the average duration of IV treatment by up to 10 days and reduced patients' hospital stays by more...Three Pfizer Inc chemists win Heroes award for epilepsy treatment for children, adults
Three research chemists from Pfizer Inc, Ann Arbor, Mich., have been named Heroes of Chemistry by the American Chemical Society, the world's largest scientific society, for developing Neurontin®, an anticonvulsant used to treat childhood as well as adult epilepsy....... The Pfizer Inc team will be honored Sept. 7 at the American Chemical Society's 226th national meeting in New York along with...Pfizers 'tune-up for life' (TM) identifies heart disease risks among race fans
NEW YORK, May 15, 2002 More than 50 percent of men and women who participated in Pfizers Tune-Up for Life™ free health screening program at Winston Cup stock car races had not seen their doctor in a year or more. Moreover, men--nearly 75 percent of those who were screened--were less likely to visit their doctor for regular check-ups than were women, according to a presentation at the Sev...